Background--Right ventricular (RV) diastolic function is impaired in patients with pulmonary arterial hypertension (PAH). Our previous study showed that elevated cardiomyocyte stiffness and myofilament Ca 2+ sensitivity underlie diastolic dysfunction in PAH. This study investigates protein modifications contributing to cellular diastolic dysfunction in PAH.
of the sarcomere, from the Z line to the M band, and consists of a linear array of proximal and distal Ig-like domains, together with N2B and PEVK segments. 3 Its stiffness is modulated by complex mechanisms involving both fast post-translational modification (phosphorylation) and slower changes in isoform expression. 4 The effect of titin phosphorylation depends on the domain targeted. Phosphorylation of the N2B domain has been shown to lower cardiomyocyte stiffness, while PEVK domain phosphorylation exerts the opposite effect. [5] [6] [7] Previously, we have shown that, unlike LV diastolic dysfunction, titin isoform composition is not changed in the RV of PAH patients. However, there is an overall decrease in titin phosphorylation in these patients. 1 Therefore, the first aim of this study was to determine the particular titin phosphorylation changes specific to the RV, which could explain the increase in RV cardiomyocyte stiffness in PAH patients.
In addition to titin-derived stiffness, RV cardiomyocytes of PAH patients are characterized by increased myofilament Ca 2+ -sensitivity, which may in turn influence cardiomyocyte lusiothropy. 8 Cardiac Troponin I (cTnI) and cardiac myosin binding protein C (MyBPC) are 2 important regulators of myofilament Ca 2+ sensitivity. [8] [9] [10] [11] [12] The second aim of this study was to determine whether changes in cTnI and MyBPC phosphorylation are related to the previously observed increase in RV myofilament Ca 2+ sensitivity.
Furthermore, fast cytoplasmic Ca 2+ clearance during diastole is crucial for a normal relaxation pattern. 13 The speed of diastolic Ca 2+ reuptake into the sarcoplasmic reticulum is determined by the activity of the sarcoplasmic reticulum Ca 2+ -ATPase-2a (SERCA2a). 14, 15 The rate at which SERCA2a transfers [Ca 2+ ] across the sarcoplasmic reticulum membrane is enhanced by PKA-mediated phospholamban (PLN) phosphorylation during b-AR stimulation. 16 The inhibitory couplingprotein PLN is removed from SERCA2a secondary to PLN phosphorylation (pPLN). Ca 2+ clearance is also regulated by the sodium-calcium exchanger 1 (NCX1) that is responsible for extracellular extrusion of 1 Ca 2+ ion in exchange for 3 imported Na + ions. 17 Previous animal model studies show the relation between altered Ca 2+ -clearance proteins and impaired cardiac relaxation. 14, 15 However, the expression and function of Ca 2+ -clearance proteins in the failing human RV is not known. Therefore, the third aim of this study was to determine whether Ca 2+ -clearance protein expression and phosphorylation is altered in the RV of PAH patients.
To summarize, the present study investigated the protein changes involved in altering RV cardiomyocyte diastolic function in patients with PAH. Our findings reveal that increased titin stiffness, reduced cTnI phosphorylation, and altered expression levels of the Ca 2+ -handling proteins contribute to RV diastolic dysfunction in PAH patients.
Methods Tissue Samples
Explanted RV tissue samples were collected from PAH patients undergoing heart transplantation (n=11) and compared with RV tissue obtained from non-failing donors (n=9) (Table) . There were no significant differences in gender and age between the 2 groups (Age PAH =36.6AE3.9, Age Don =41.1AE4.7, P=0.47, Gender(F/M) PAH =11/1, Gender (F/M) Don =6/3 P=0.28). Human cardiac tissue collection and use by collaborating universities (VU Medical Center, Amsterdam) was approved by the Human Research Ethics Committee of The University of Sydney (AU/1/961515) and the Universit e Paris-Sud-Inserm U999 (ID RBC 2008-A00485-50). All patients received treatment previous to cardiac transplantation corresponding to the clinical protocols present at the time of the intervention. Various treatments (acute Dobutamine administration) may be associated with the differences observed between patients. After transplantation, RV tissue samples were immediately frozen and stored in liquid nitrogen, preserving the expression and phosphorylation level of the cardiomyocytes. No.IPFL00010, 045 lm) and probed with the relevant antibodies. Membranes were scanned and analyzed using Odyssey Infrared Imaging System (Li-COR Biosciences). N2B and N2BA protein content was determined on Ponceau-S-stained membranes and used to normalize for phosphorylation level. 5 
RV Cardiomyocyte Diastolic Stiffness
RV free wall tissue samples (between 20 and 40 mg) were defrosted in relaxing solution then sectioned in smaller pieces with a fine dissection scissors. Subsequently, single cardiomyocytes were isolated from these tissue pieces by manual mechanical homogenization. The single cells were then membrane permeabilized by adding Triton (1%) to the relaxing solution in order to wash out the lipid cellular membranes. The cell solution was repeatedly washed with relaxing solution in order to remove Triton. The cell yield is somewhat variable, depending on the initial amount of tissue, the release of cardiomyocyte from the tissue bulk during mechanical homogenization and the loss of cells during Triton washing. Cells for force measurements were chosen based on length and width (length: 50 to 100 lm, width 15 to 30 lm at rest in relaxing solutions). 1 A minimum of 3 cells per sample was used to determine diastolic stiffness and the average was used for further statistic analysis. A single cell was attached with silicone adhesive between a force transducer and a piezoelectric motor. To determine cardiomyocyte stiffness a 25% shortening was performed in the relaxing solution and steady-state stiffness measurements were recorded at increasing sarcomere lengths (1.8 to 2.4 lm).
1
Cardiomyocytes were further incubated in relaxing solution with PKA (100 U/mL) (Protein Kinase A Catalytic subunit from bovine heart, P2645; Sigma-Aldrich) (donor n=4, PAH n = 4), CamK IId (50 U/mL) or PKC-subunit a (10 U/mL) (Protein Kinase C a human isozyme, P1782; Sigma-Aldrich) (donor n=3, PAH n=3) at 20°C for 1 hour. PKC a also requires Ca 2+ , therefore the relaxing solution was mixed in a 1:1 concentration ratio with a Ca 2+ -containing solution of pCa 5.8, obtaining
therefore an end pCa of 5.9 in which the cardiomyocytes were incubated. Diastolic stiffness was recorded after PKA, PKCa, or CamK IId incubation. 19 Individual force values were normalized by the cardiomyocyte cross-sectional area recorded at 2.2 lm sarcomere length.
Sarcomeric Protein Phosphorylation
Sarcomeric protein phosphorylation was determined for each tissue sample (donor n=9, PAH n=11). RV tissue samples were homogenized and separated on gradient gels (NuPAGE 
2+ -Handling Proteins Expression and Phosphorylation
To determine SERCA2a expression, monoclonal rabbit antibody was used (courtesy of Warner S. Simonides, VU University Medical Center) (donor n=9, PAH=11). PLN binds to and inhibits SERCA2a, while phosphorylation of PLN (pPLN) removes the inhibitory binding of PLN and promotes SERCA2a activity. PLN and pPLN were determined with the following antibodies: total PLN (L15, sc21923; Santa Cruz Biotechnology, Inc), PKAspecific PLN phosphorylation site (Ser16, sc12963; Santa Cruz Biotechnology, Inc), and CaMK IId -specific PLN phosphorylation (Thr17, A010-13AP; Badrilla). NCX1 expression was quantified using NCX1-C2C12 antibody (ab2869; Abcam). Cardiac specific Ryanodine Receptor 2 expression was also quantified (C3-33; ThermoFisher Scientific). The amount of protein expression or phosphorylation was normalized to the concentration of Ponceau-S-stained actin.
Statistical Analyses
Statistical analyses were performed using Prism 5 for Windows (GraphPad Software Inc and IBM â SPSS â Statistics 20.0; IBM Corporation). P values lower than 0.05 were considered significant. All data are presented as meanAESEM.
Age differences between patients were tested for significance by a non-paired t test. Gender differences were tested by a Fisher's exact test. Changes in protein expression were tested for significance by a non-paired, non-parametric Mann Whitney U test. Phos-Tag TM analysis was tested for significance by repeated 2-way ANOVA followed by the Bonferroni post-hoc test.
The effects of PKA, PKCa, and CamK IId incubation in PAH patients and donors at increasing sarcomere lengths were tested by using a mixed-design ANOVA with disease as between-group measure, sarcomere length and PKA/PKCa/ CamK IId -incubation as repeated measures. The greenhouseGeisser correction was used, because sphericity could not be assumed.
Results

PKA-Mediated Titin Phosphorylation is Reduced in PAH RV Cardiomyocytes
Cardiomyocyte stiffness is modulated by titin isoform composition and phosphorylation. In our previous study we showed that titin isoform ratio (N2BA/N2B) is not significantly changed in PAH compared with donors (N2BA/N2B Don =0.91AE0.08, N2BA/N2B PAH =0.77AE0.07, P=0.20).
1 Therefore, the overall increase in cardiomyocyte stiffness may be a consequence of titin N2B or PEVK domain phosphorylation. Titin phosphorylation was determined using phosphospecific antibodies for PKA and PKCa phosphorylation sites. We found significantly reduced levels of PKA-dependent phosphorylation of N2B serine 469 site and PKCa-dependent phosphorylation of PEVK serine 170 site (PKA Don =1.00AE0.03, PKA PAH =0.44AE0.04, P=0.002; Figure 1A1 ) and (PKCa-S170 Don =1.00AE0.06, PKCa-S170 PAH =0.46AE0.06, P=0.002; Figure 1B1 ). No significant difference was found in PKCadependent phosphorylation of PEVK serine 26 (PKCa-S26 Don =1.00AE0.12, PKCa-S26 PAH =0.96AE0.12, P=0.53; Figure 1B2 ).
Activation of CamK IId determined indirectly by assessing the level of PLN CamK IId -dependent phosphorylation of the residue threonine at position 17, which is an exclusive specific site for CamK IId . 21 We found no statistical significant difference between the 2 groups (CamK IIdDon =1.00AE0.19, CamK IIdPAH =1.42AE0.29, P=0.41; Figure 1C1 ).
PKA Incubation Partially Restores RV Cardiomyocyte Stiffness
Subsequently, we tested in a subgroup of samples the functional relevance titin PKA PKCa and CamK IId -mediated phosphorylation. For this purpose, membrane-permeabilized cardiomyocytes in relaxing solution were used to minimize the influence of additional determinants of cardiomyocyte stiffness such as membrane and sarcoplasmic reticulum Ca 2+ -handling. Therefore, cardiomyocyte stiffness is attributed solely to the sarcomeric protein titin. RV cardiomyocyte stiffness was measured at increasing sarcomere lengths, starting at 1.8 lm and stretched to 2.0, 2.2, and 2.4 lm. After PKA incubation we recorded a significant decrease in PAH cardiomyocyte stiffness. Donor cardiomyocyte stiffness was minimally affected by PKA incubation (P interaction PKA9disease=0.01; Figure 1A2 ). PKCa incubation significantly increased cardiomyocyte stiffness in PAH samples and had little effect on donor cardiomyocyte stiffness (P interaction PKCa*disease=0.09; Figure 1B3 ). Cam-K IId incubation decreased cardiomyocyte stiffness of both Don and PAH samples (P interaction CamK IId *disease=0.08; Figure 1C2 ). Similar stretch or incubation in relaxing solutions without kinases would not modify baseline cardiomyocyte stiffness. Figure 2 ). Cardiac troponin T (cTnT) phosphorylation appeared to be higher in PAH compared with donors; however, this was not statistically significant (cTnT Don = Figure 3A) . The cTnI PKA specific phosphorylation site (serine 22/23) showed significantly lower phosphorylation in PAH samples compared with 469 PKΑ-dependent phosphorylation. Typical example of the 2 titin isoforms (upper band: N2BA; lower band N2B) immunostained with phosphospecific antibody against serine 469 site on titin N2B domain and the corresponding Ponceau S staining for total titin (n Don =7, n PAH =5). A2. Donor and PAH cardiomyocyte stiffness was measured in relaxing solution at increasing sarcomere length (1.8 to 2.4 lm)-continuous line. The same cardiomyocyte was further incubated with PKA active subunit and stiffness measurements were repeated-dotted line (n Don =4, n PAH =4). B-B1. Titin PEVK domain serine 170 PKCa-dependent phosphorylation. Typical example of the 2 titin isoforms (upper band: N2BA; lower band N2B) immunostained with phosphospecific antibody against serine 170 site on titin PEVK domain and the corresponding Ponceau S staining for total titin (n Don =7, n PAH =5). B2.Titin PEVK domain serine 26 PKCa-dependent phosphorylation. Typical example of the 2 titin isoforms (upper band: N2BA; lower band N2B) immunostained with phosphospecific antibody against serine 26 site on titin PEVK domain and the corresponding Ponceau S staining for total titin (n Don =7, n PAH =5). B3. Donor and PAH cardiomyocyte stiffness was measured in relaxing solution at increasing sarcomere length (1.8 to 2.4 lm)-continuous line. The same cardiomyocyte was further incubated with PKCa active subunit and stiffness measurements were repeated-dotted line (n Don =3, n PAH =3). C-C1. Phospholamban threonine 17 CamK IId -dependent phosphorylation was used as an indirect measurement of titin CamK IId phosphorylation. The phosphorylation level was normalized to the total amount of Phospholamban present in the sample (n Don =7, n PAH =11). C2. Donor and PAH cardiomyocyte stiffness was measured in relaxing solution at increasing sarcomere length (1.8 to 2.4 lm)-continuous line. The same cardiomyocyte was further incubated with CamK IId and stiffness measurements were repeated-dotted line (n Don =3, n PAH =3). Data presented as meanAESEM. CamKIId indicates calmoduling-dependent-kinase; PAH, pulmonary arterial hypertension; PKA, protein-kinase-A; PLN, phospholamban.
Reduced Phosphorylation of Sarcomeric cTnI
donors (cTnI-S22/23 Don =1.00AE0.08, cTnI-S22/23 PAH =0.41 AE0.11, P=0.002; Figure 3B ).
Phos-Tag TM analysis demonstrated that the distribution of cTnI phosphorylation (unphosphorylated [P 0 ], mono-phosphorylated [P 1 ], and bis-phosphorylated [P 2 ]) in PAH-cardiomyocytes was shifted to more unphosphorylated cTnI in comparison to donors, evident from higher levels of unphosphorylated cTnI and lower levels of bis-phosphorylated cTnI (P Don 0/1/2=38.38AE11.55%/20.78AE3.57%/40.84AE 14.21%, P PAH 0/1/2=67.28AE5.86%,/21.55AE3.12%/11.17AE 3.69%, P interaction =0.008; Figure 3C ).
Altered Expression of Ca
2+ -Handling Proteins
SERCA2a expression was significantly lower in PAH cardiomyocytes (SERCA2a Don =1.00AE0.14, SERCA2a PAH =0.56 AE0.09, P=0.02; Figure 4A ). Total PLN protein levels were higher in PAH, however, the difference failed to reach statistical significance (PLN Don =1.00AE0.13, PLN PAH =2.44AE 0.65, P=0.23; Figure 4B ). PLN phosphorylation was determined as a ratio calculated from total PLN protein level in relation to the amount of phosphorylated PLN. pPLN was significantly lower in PAH compared with donors (pPLN/ PLN Don =1.00AE0.12, pPLN/PLN PAH =0.55AE0.10, P=0.02; Figure 4C ). The inhibitory effect of PLN on SERCA2a was determined by the PLN/SERCA2a ratio, which was higher in PAH compared with donors (PLN/SERCA2a Don =1.5AE0.47, PLN/SERCA2a PAH =5.71AE1.67, P=0.19; Figure 4D ) In addition, the lower level of NCX1 protein level in PAH was not statistically significant (NCX1 Don =1.00AE0.28, NCX1 PAH =0.55AE0.12, P=0.36; Figure 4E ). The expression level of RyR2, responsible for systolic Ca 2+ release from the sarcoplasmic reticulum was not significantly different in the 2 groups (RyR 2Don =1.00AE0.05, RyR 2PAH =1.26AE0.13, P=0.11; Figure 4F ). 
Titin Determined Cardiomyocyte Stiffness
This is the first human study to show altered titin phosphorylation and its functional consequence in the failing right ventricle. We demonstrate that in RV tissue from PAH patients, titin serine 469 (PKA site) and serine 170 (PKCa site) phosphorylation are significantly reduced.
No change was observed in titin serine 26 (PKCa site) phosphorylation between PAH and donor. Interestingly, these findings differ from those previously observed in LV pressure overload animal models. Hudson et al investigated titin phosphorylation in a mouse model of hypertensive left heart failure induced by transverse aortic constriction. 22 They concluded that increased PKCa-mediated phosphorylation of serine 26 in the PEVK domain was the main contributor to left ventricular cardiomyocyte stiffness. No significant change in PKA-mediated phosphorylation of the N2B domain was found in this animal model of left heart failure. K€ otter et al used end-stage human LV tissue obtained during heart transplantation from hypertrophic cardiomyopathy (HCM) and idiopathic dilated cardiomyopathy (iDCM) patients and concluded that the significant increase in PEVK domain serine 26 (PKCa site) phosphorylation, together with altered titin N2B domain phosphorylation, A B C Figure 3 . cTnI phosphorylation. A, Typical example of donor and PAH samples immunostained against the unphosphorylated form of cTnI and normalized for Ponceau-S stained actin. cTnI total phosphorylation was determined by Western blot analysis in donor and PAH samples (n Don =8, n PAH =9). B, Typical example of donor and PAH samples immunostained against cTnI serine 22/23 residue and normalized for Ponceau-S stained actin. cTnI serine 22/23 phosphorylation was determined by Western blot analysis in donor and PAH samples (n Don =9, n PAH =11). C, Typical example of donor and PAH samples immunostained against unphosphorylated (P 0 ) cTnI, mono-phosphorylated (P 1 ) cTnI and bis-phosphorylated (P 2 ) cTnI. cTnI relative phosphorylation distribution was determined by Phos-Tag analysis in donor and PAH samples (n Don =5, n PAH =9). Data presented as meanAESEM. cTnI indicates cardiac troponin I; cTnT, cardiac troponin T; PAH, pulmonary arterial hypertension.
determine the increase cardiomyocyte stiffness in LV failure. 23 This suggests that while in LV failure PKCa-dependent hyperphosphorylation of titin PEVK domain serine 26 plays a key role in increasing stiffness, in RV failure secondary to pressure overload, PKA-dependent hypophosphorylation of N2B domain serine 469 in central in increasing cardiomyocyte stiffness.
To demonstrate the functional relevance of altered serine 469 and serine 170 phosphorylation, we incubated RV cardiomyocytes with the catalytic subunits of PKA and PKCa and measured the effects on RV cardiomyocyte stiffness. We observed that PKA incubation lowered stiffness only in PAH and largely restored RV cardiomyocyte stiffness to values observed in donors. In contrast, PKCa incubation increased cardiomyocyte stiffness in both PAH but far less in donor. At sarcomere lengths longer than physiological (>2.2 lm), PKCa incubation resulted in a large increase in RV cardiomyocyte stiffness in PAH patients. These findings suggest that titin serine 469 (PKA site) hypophosphorylation is the main contributor to RV diastolic stiffness in PAH, rather than titin serine 170 (PKCa site) hypophosphorylation. The latter may be a compensatory mechanism to prevent further increase in titin stiffness in RV cardiomyocytes in PAH patients.
In addition to PKA-, PKCa-, and CaMK IId -dependent phosphorylation, titin stiffness is subject to the fine-tuning of a number of different kinases with opposite or complementary effects. In humans, protein kinase G (PKG) was shown to phosphorylate N2B serine 469 with the same functional effect as PKA. 24 In addition to PKA and PKG, recent data show that extracellular-signal-regulated kinase 2 (ERK2) can decrease titin stiffness. However, the phosphorylation site is still to be resolved. 25 Furthermore CaMK IId was shown to phosphorylate N2B (other sites than PKA) and PEVK domains and overlap with PKCa phosphorylation sites on the PEVK domain. 21, 26 However, the functional role of these novel phosphorylation pathways was not yet shown in humans. 2+ -ATPase 2a (cardiac isoform) expression level (n Don =9, n PAH =11). B, Total PLN: phospholamban expression level (n Don =7, n PAH =10). C, PLN (Ser16)/ Total PKA-dependent phosphorylation level of serine 16 residue on PLN normalized to total PLN protein content (n Don =7, n PAH =9). D, PLN/SERCA2a inhibitory effect of PLN on SERCA2a quantified by the ratio between 2 (n Don =8, n PAH =9). E, NCX1, Na + /Ca 2+ exchanger 1 (cardiac isoform) expression level (n Don =9, n PAH =11). F, RyR2, ryanodine receptor 2 (cardiac isoform) expression level (n Don =9, n PAH =11). Data presented as meanAESEM. PAH indicates pulmonary arterial hypertension; PLA, protein-kinase-A; PLN, phospholamban. 
PAH and Excessive Neurohormonal Activation
Although the 3 mechanisms discussed here clearly affect diastolic function in a distinct way and therefore may have different relevance in vivo, we observe a common factor to all 3 mechanisms: reduced PKA-mediated phosphorylation. Decreased PKA phosphorylation determined increased titinderived RV cardiomyocyte stiffness, increased myofilament cTnI dependent Ca 2+ sensitivity, and altered Ca 2+ clearance due to reduced PLN phosphorylation. In the setting of heart failure, disturbed PKA phosphorylation is attributed to impaired b-AR signaling as a consequence of increased neurohormonal stimulation and compensatory receptor b-AR downregulation. 28 In PAH, however, the consequences of increased neurohormonal activation are less well understood. 30 Bristow et al observed decreased b-AR density in failing RV myocardium. 31 In addition, reducing neurohormonal activity in an experimental model of PAH resulted in improved RV diastolic function and partially restored sarcomeric protein phosphorylation (cTnI and cMyBPC). 32 Therefore, we propose that in PAH patients the reduced PKA-mediated phosphorylation of titin, cTnI, and PLN are at least partially caused by increased neurohormonal activation.
Clinical Implications
Beta-blocker therapy is known to counteract the loss of function of b-AR signaling by restoring b-AR density, followed by the restoration of PKA-mediated phosphorylation. 32, 33 In a previous experimental PAH model, rats receiving beta-blocker therapy showed a significant reduction in RV diastolic stiffness and increase in cTnI and cMyBPC phsophorylation compared with PAH rats receiving placebo. These effects are likely due to reduced neurohormonal activation in PAH rats receiving beta-blockers, normalization of b-adrenergic stimulation, and increased PKA-mediated titin, cTnI, and MyBPC phosphorylation. Although well tolerated in PAH rats, betablockers are currently not recommended in PAH due to possible negative inotropic effects. Nevertheless, based on the beneficial effects of beta-blockers in PAH experimental models, we have initiated a phase II clinical study to investigate the safety and efficacy of beta-blocker (Bisoprolol) in patients with PAH (Clinicaltrials.gov identifier: NCT01246037). 32 The future results of this study will reveal whether indeed, b-AR/PKA signaling pathway is a novel therapeutic target for RV diastolic impairment in PAH patients.
Limitations
Efficient diastolic Ca 2+ clearance is vital for ensuring proper relaxation for the sarcomere; therefore in this study we quantified the expression level of the most important proteins involved in Ca 2+ handling. However, the functional relevance of these changes was not assessed. Functional relevance can only be determined in freshly harvested myocardial tissue/ whole hearts, usually from animal models where changes in protein levels are consequently related to the functional data. In our study we used human myocardial tissue preserved by freezing, which did not alter the protein level and phosphorylation status, however made functional assessments impossible. Nevertheless, previous animal model studies show a clear relation between expression levels and function of Ca 2+ -handling proteins; therefore we speculate that this is also the case in our study. 13 There are several other mechanisms, which regulate diastolic dysfunction such as: increased radical oxygen species production, T-tubules loss, or disorganization of cardiomyocyte cytoarchitecture. Although important for diastolic function, this study only focused on the cardiomyocyte stiffness, myofilament Ca 2+ sensitivity, and altered Ca 2+ -clearance protein levels. 34 
